Last reviewed · How we verify
Continuous infusion of cefoxitin
Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis, Intra-abdominal infections, Gynecological infections.
At a glance
| Generic name | Continuous infusion of cefoxitin |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cefoxitin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. As a second-generation cephalosporin, it has broader gram-negative coverage than first-generation agents and is particularly effective against anaerobic bacteria. Continuous infusion delivery maintains sustained bactericidal concentrations at the infection site.
Approved indications
- Surgical site infection prophylaxis
- Intra-abdominal infections
- Gynecological infections
- Mixed aerobic-anaerobic infections
Common side effects
- Hypersensitivity reactions
- Diarrhea
- Phlebitis at infusion site
- Nausea
- Clostridium difficile-associated diarrhea
Key clinical trials
- Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery (PHASE3)
- Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous infusion of cefoxitin CI brief — competitive landscape report
- Continuous infusion of cefoxitin updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI